Skip to main content
NCBI home page
Cancer Microenvironment logoLink to Cancer Microenvironment
. 2015 Feb 5;8(1):43–44. doi: 10.1007/s12307-015-0165-y

Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

M Vogelhuber 1, S Feyerabend 2, A Stenzl 2, T Suedhoff 3, M Schulze 4, J Huebner 5, R Oberneder 6, W Wieland 7, S Mueller 8, F Eichhorn 9, H Heinzer 10, K Schmidt 11, M Baier 11, A Ruebel 11, K Birkholz 11, A Bakhshandeh-Bath 12, R Andreesen 1, W Herr 1, A Reichle 1,✉
PMCID: PMC4449342  PMID: 25651886

Erratum to: Cancer Microenvironment

DOI 10.1007/s12307-014-0161-7

The original publication of this article (10.1007/s12307-014-0161-7) unfortunately contained an error. Figures 1 and 2 are the same, the correct figures are presented here.

Fig. 1.

Fig. 1

Open in a new tab

Study design including the main inclusion and exclusion criteria. ECOG Eastern cooperative oncology group performance status, CRPC Castration-resistant prostate cancer, PSA Prostate-specific antigen, AE Adverse event, SAE Serious adverse event

Fig. 2.

Fig. 2

Open in a new tab

Proportion of patients discontinuing study drug. One patient is still ongoing (at the time of manuscript submission Oct 2014). Pts Patients, PSA Prostate-specific antigen

Footnotes

The online version of the original article can be found at 10.1007/s12307-014-0161-7.

Articles from Cancer Microenvironment are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES